ȿռԤΤ
ץ

ޡȡץȾϤޤӥͥޥ󡢱̿ĩढʤΤ긵ء

2012ǯ05

ǤϤʤۥե륻ϡ


ϤΥѥեޥ󥹤ͭפʤΤ


ӥǥ󥹤ˤʤ뤫Ȼפޤ



ۥե륻ϡ

륳ưʥץǽγ [7]


ʥãϤؤθ [8] [9]


ƿݸѤͭƤޤ


ȤСʥӥǥ󥹡

ʥͥߤ˥ۥե륻 (200mg/kg,5) 򤢤餫ͿƤ顢

Ǿƣˡ

CA1ΰ (ˤϽפΰǤ) Υ˥塼ؤθ̤Ĵ٤


ȥۥե륻Ϳϡץ饻ܷ١˥塼ؤΥ᡼ڸƤ[10]


뤤ϡ

Dz٤αɤ򵯤ǾȿФ (ȱֺ˦ȿ򹶷⤹륱)

ۥե륻ϤαɤƯ򤷤Ƥޤ[13]




ۥե륻ϡĹҼοä뤫⤷ޤ

Ĺ (Nerve growth factor: NGF) Ȥϡ

ȯã򤦤ʤǽϤ餫륿ѥǤ[14]


ƯϡNGF (ϤǾΥ˥塼ɽ̤¸ߤƤޤ) ˡ

ĹҡNGFˤ礹뤳Ȥǵޤ




NGFοϡȼ뤳ȤʬäƤޤ

åȤμ¸ˤƥۥե륻ϡ

NGFοäƤޤ[15]


줬̣뤫Ȥȡ

˥塼ιϷѡǤ


ޤʸˤϡεҤ⸫ޤ


ˤäơ˥塼μ͵Υѥ̩١˥塼ο礭ϸƤ椭ޤ

Ϸͥߤ˥ۥե륻 (50mg/kg,24) Ϳ̤Ǥϡ

Τ褦ʸǧʤä[15]




ۥե륻ιȥ쥹Ѥ⸫ƨȤϤǤޤ

ȥ쥹Ǥϡ뤬ޤ

ΥۥμΤϡǾ (Ȥ˳) ʢ¿ȤΤƤޤ

ȥ쥹Ͽ徺׹ͤᤰ餻ʢˤϤäפȻä򤿤ᤳޤޤ


ͶƳ⡢ΰǤ


ʥλϡ˥塼Ⳳޤ

ϥ˥塼μΤɷ㤷

˥塼Ρֶʳ 򾷤Ǥ


ʳȤϡ

륷।󤬺˦˲ή뤳Ȥǡ

˥塼󤬲ư򵯤˻Ȥᥫ˥Ǥ

ۥե륻ϡβ껺褦Ǥ

ȥȥ졼˥󥰤ǡСȥ졼˥󥰤ˤʤä˥ۥե륻 (800 /) ݼ褷Ȥ

ȯᥫ˥Ǥ뾲--շϤѲ⤿餷뻺㲼[16,17,18]


ʤ礦Ȥϰۤʤޤ˥塼ζʳФƤϡͻ˴ޤޤͭʬͭפǤ

ͭʬϡ˥塼Υ륷।ͥľܺѤʳޤ롢Ȥӥǥ󥹤ޤ




ۥե륻ϡѤͭƤ褦Ǥ

԰¾㳲䤦ľɾβ[20]

ʡҸǽϤξ徺ǧ줿[16,19,20,21]




ȤǡǾͭפȤ륵ץȤФ뺬ŪʵϡʪǾϤΤ

ä⡢ޤ


ʤʤ顢Ǿؤ̤BBB (Ǿ) ̤ȴ뤳ȤϡѺǤ


ۥե륻ϡиݼˤƤ⡢ǾܹǧƤޤ[10]



ǤϺǸ

ۥե륻ϡɤΤ餤̤ݤɤΤǤ礦


ͤϡ100 ʾݼ褬ͭǤ[22]




ڷ

Ǿη򹯤ˤϡۥե륻100 ݼ褹뤳ȡ

ȥ쥹¿ȿռԤƬǾϡˡ祦ե120 äݤɤǤ礦


ͤޤǤˡ¸Ƥ륵ץȤϡ

SWITCH HYPER SWITCH COOL SWITCH Ǥ


ʬ̤۹礵Ƥޤ

ʬץˡ

祦ե120
ۥե륻100
ͻ200 COOL SWITCH ϥꥫͻ200mg
Хѥ˥饨80ӡ


ǾΥѥեޥ󥹤򤷤äݤϡ

SWITCHCOOL SWITCH HYPER SWITCH ѤƤߤƤϤǤ礦
switch %282%29

hyper_switch %282%29

cool_switch01ڼ

ޥŷǤǤޤ

iStock_000005716223XSmall






[1] Kidd PM. 1999. A review of nutrients and botanical in the integrative management of cognitive dysfunction. Altern Med Rev 4:38-43
[2] Bruni A,Toffano G.1982. Lysophophatidylserine, a short-lived intermediate with plasma membrane regulatory properties. Pharmaco Res Commun 14(6):469-484
[3] Yoshimura T, Sone S. 1990 Role of phosphatidylserine in membrane actions of tumor necrosis factor and interfoerons alpha and gamma. Biochem Int 20(4):697-705
[4] Cohen SA,Mueller WE.1992. Age related alterations in the mouse forebrain:partial restoration by chronic phosphatidylserine treatment. Brain Res 584: 174-180
[5] Moynagh PN, Williams DC.1992. Stabilization of the peripheral-type benzodiazepine acceptor by specific phospholipids. Biochem Pharmacol 43(9): 1939-1945
[6] D.O.Kennedy, C.F Haskell, P.L Mauri, A.B Scholey.2007. Acute cognitive effects of standardized Ginkgo biliba extract conplexed with phosphatidylserine. Hum.Psychopharmacol Clin Exp 2007 ;22:199-210
[7] Pedata F et.al. 1985. Phosphatidylserine increases acetylcholine release from cortical slices in aged rats. Neurobiol Aging 6(4): 337-339
[8] Benowitz LI et.al. 2000. GAP-43:an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 20(2):84-91
[9] Gianotti C et.al. 1993. B-50/GAP-43 phosphorylation in hippocampal slices from aged rats: effects of phosphatidylserine administration. Neurobiol Aging 14(5): 401-406
[10] , ƣ . 2010. Ʀۥե륻Ǿǽ Anti-aging Science 2(2): 57-61
[11] Calderon C, Huang ZH, Gage DA, et.al. 1994. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidylserine. J Exp Med 180: 945-958
[12] Venema RC, Sayegh HS, Arnal JF, et.al. 1995. Role of enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J Bio Chem 270: 14705-14711
[13] Monastra G,Gross AH, Bruni A et.al. 1993. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelinaction. Neurology 43: 153-163
[14] Angelucci L, Ramacci MT, Taglialatela G, et.al. 1988. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neuroscience Res 20:491-496
[15] Nunzi MG, Milan F, Guidolin D, Toffano G. 1987. Dendritic spine loss in hippocampus of aged rats Effect of brain phosphatidylserine administration. Neurobiol Aging 8:501-510
[16] Cenacchi T, Bertoldin T, Farina C, et.al. 1993. Cognitive decline in the elderly: a double-blind,placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano) 5:123-133
[17] Monteleone P,Beinat L, Tanzillo C, et.al. 1990. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52:243-248
[18] Monteleone P, Maj M, Beinat L, et.al. 1992. Blunting by chronic hosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol 42:385-388
[19] Maggioni M, Picotti GB, Bondiolotti GP,et.al. Effects of hosphatidylserine therapy in geriatric patients with depressive disdoers. Acta psychiatr Scand 81:265-270
[20] Crook T,Petrie W, Wells C, Massari DC. 1992. Effects of phosphatidylserine in Alzheimers disease. Psychopharmacol 42:385-388
[21] Amaducci L. 1988. Phosphatidylserine in the treatment of Alzheimers disease: results of a multicenter study. Psychopharmacol Bull 24:130-134
[22] Parris M. 1999. A review of nutrients and botanicals in the integratetive management of cognitive dysfunction. Alternative Medicine Review 4(3):144-161

ϡۥե륻 ˤĤƤΤä

ä

Ǥ륨ӥǥ󥹤鸫ơۥե륻ϡ

ǾΥѥեޥ󥹤˹ǽ⤤

ǤϡΥӥǥ󥹤Ȥϡ

ۥե륻ϡϤΥѥեޥ󥹤롣

ϡۥե륻ȥ祦եȤ߹碌֤٤Ǥ礦

Ǥϡʬ̤Ȥϡ



ǤϾܺ٤Ǥ

ޤϡۥե륻ȤϤʤǤ뤫


ۥե륻ϡ˦ΤҤȤġ


ʹ֤κ˦ϡ٤ƤλޤǤꡢ¸ɬפʵǽϡΥۥե륻äƤ롢ȸȤǤޤ


ȤС

̿ưΥͥ륮λ (ATP)


̿ǽݤĤΥΥۥᥪǽ


˦٥ǤγԳʤɤʤɡ


ƥۥե륻ϡȤˡ˥塼䥷ʥץ¿¸ߤ[1]


륳ɡѥߥ󡢥Υ륢ɥʥȤäãʪФ䥷ʥã˴ͿƤޤ[2,3,4,5]


ۥե륻ΡƬǾؤͭˤĤơʳŪϼθ̤𤷤Ƥޤ


Ϥβ


ݸ


ȥ쥹


ĺ


Ǿη򹯤ˤʤˡۥե륻ϡǤ֤ΥץꡢǤϤʤǤ礦



ǤϡʸϤǤ礦


ʿǯ20.4Фηͤоݤˤ祦եȥۥե륻ȤȤ߹碌ĴΤǤ


Ȥ߹碌Ϥ


1) 祦ե120 ñΤݼ褷硣


2) 祦ե120 ȥۥե륻 (PS) 360 Ʊݼ褷硣


3) 祦ե120 ȥۥե륳 (PC) 360 Ʊݼ褷硣


λѥǡָ


ϤΥԡɡ


Ϥ


ֵϤΥԡɡ


ֵ


󼡵


֥󥰥꡼ Ĵ٤Ƥޤ





) 祦եȥۥե륻 Ȥ߹碌Ǥ̤ι⤤Ȥ߹碌ä褦Ǥ


ϤΥԡɡ ˤƤ

祦եñȤ1)

祦եPC3)

2.5ָޤͭդ®ʤä


ơ祦եPSƱݼ 2) ϡ

ˡ6ָˤƤͭդ®

祦եȥۥե륻PSˤϡϤΥԡɤˤơɤ褦Ǥ


Ϥ Ǥ


祦եPS 2) Ȥ߹碌ͭդʲߤ줿

⥤祦եȥۥե륻PSˤɤ褦Ǥ


ֵΥԡɡ Ǥ


祦եPC 3) 4ָ˵դ٤ʤä

祦եPS 2) ϡ

ݼ裱֤飶ָΤ٤Ƥͭդ˲[6]


ΥȥϡΤ褦˽񤭴٤⤷ޤ


ǾΥѥեޥ󥹤Τˤϡۥե륻ȥ祦եĤʻݤ٤Ǥ


ǤϤʤۥե륻ϵϤΤǤ礦

Ȥ³ϡѡȣǡ


ͤޤǤ

嵭祦եȥۥե륻Ȥ߹碌Ƥ륵ץȤϡ

󤫤ȯ䤵Ƥ륹åΤƤޤ

å ץˤϡ
祦ե120mg
Ʀ쥷ʪʥۥե륻ͭ100mg
ͻ200mg
Хѥ˥饨80mg äƤޤ


ͻȤСγϤΤƤ⤤ޤ

¤ϡͥ줿ޡȥϡ֤Ǥ⤢ꡢǧεǽͭѤǤ

祦ե120mgȹͻ200mgȤ߹碌ϡ

ϤϤͭס


ˡ祦ե ȥꥫͻȤ߹碌ϡ

ϤؤΥݡϤͻ⤤褦Ǥ


ϤΥե˽򤪤ϡ

ꥫͻä COOL SWTCH ɤ⤷ޤ


ĤŤ

switch %282%29

hyper_switch %282%29

cool_switch01ڼ



[1] Kidd PM. 1999. A review of nutrients and botanical in the integrative management of cognitive dysfunction. Altern Med Rev 4:38-43
[2] Bruni A,Toffano G.1982. Lysophophatidylserine, a short-lived intermediate with plasma membrane regulatory properties. Pharmaco Res Commun 14(6):469-484
[3] Yoshimura T, Sone S. 1990 Role of phosphatidylserine in membrane actions of tumor necrosis factor and interfoerons alpha and gamma. Biochem Int 20(4):697-705
[4] Cohen SA,Mueller WE.1992. Age related alterations in the mouse forebrain:partial restoration by chronic phosphatidylserine treatment. Brain Res 584: 174-180
[5] Moynagh PN, Williams DC.1992. Stabilization of the peripheral-type benzodiazepine acceptor by specific phospholipids. Biochem Pharmacol 43(9): 1939-1945
[6] D.O.Kennedy, C.F Haskell, P.L Mauri, A.B Scholey.2007. Acute cognitive effects of standardized Ginkgo biliba extract conplexed with phosphatidylserine. Hum.Psychopharmacol Clin Exp 2007 ;22:199-210
[7] Pedata F et.al. 1985. Phosphatidylserine increases acetylcholine release from cortical slices in aged rats. Neurobiol Aging 6(4): 337-339
[8] Benowitz LI et.al. 2000. GAP-43:an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 20(2):84-91
[9] Gianotti C et.al. 1993. B-50/GAP-43 phosphorylation in hippocampal slices from aged rats: effects of phosphatidylserine administration. Neurobiol Aging 14(5): 401-406
[10] , ƣ . 2010. Ʀۥե륻Ǿǽ Anti-aging Science 2(2): 57-61
[11] Calderon C, Huang ZH, Gage DA, et.al. 1994. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidylserine. J Exp Med 180: 945-958
[12] Venema RC, Sayegh HS, Arnal JF, et.al. 1995. Role of enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J Bio Chem 270: 14705-14711
[13] Monastra G,Gross AH, Bruni A et.al. 1993. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelinaction. Neurology 43: 153-163
[14] Angelucci L, Ramacci MT, Taglialatela G, et.al. 1988. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neuroscience Res 20:491-496
[15] Nunzi MG, Milan F, Guidolin D, Toffano G. 1987. Dendritic spine loss in hippocampus of aged rats Effect of brain phosphatidylserine administration. Neurobiol Aging 8:501-510
[16] Cenacchi T, Bertoldin T, Farina C, et.al. 1993. Cognitive decline in the elderly: a double-blind,placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano) 5:123-133
[17] Monteleone P,Beinat L, Tanzillo C, et.al. 1990. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52:243-248
[18] Monteleone P, Maj M, Beinat L, et.al. 1992. Blunting by chronic hosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol 42:385-388
[19] Maggioni M, Picotti GB, Bondiolotti GP,et.al. Effects of hosphatidylserine therapy in geriatric patients with depressive disdoers. Acta psychiatr Scand 81:265-270
[20] Crook T,Petrie W, Wells C, Massari DC. 1992. Effects of phosphatidylserine in Alzheimers disease. Psychopharmacol 42:385-388
[21] Amaducci L. 1988. Phosphatidylserine in the treatment of Alzheimers disease: results of a multicenter study. Psychopharmacol Bull 24:130-134
[22] Parris M. 1999. A review of nutrients and botanicals in the integratetive management of cognitive dysfunction. Alternative Medicine Review 4(3):144-161

ϡեե륻 ˤĤƤΤä

ä

Ǥ륨ӥǥ󥹤鸫ơեե륻ϡǾΥѥեޥ󥹤˹ǽ⤤Υӥǥ󥹤Ȥϡ

ϤΥѥեޥ󥹤롣ϡեե륻ȥ祦եȤ߹碌֤٤Ǥ礦ʬ̤ϡ

嵭ץΤҤȤĤϥ SWITCHޤCOOL SWITCH

SWITCH ȤϤʤˤ



ǤϾܺ٤Ǥ

եե륻ϡ˦ΤҤȤġ

ʹ֤κ˦ϡ٤ƤλޤǤꡢ¸ɬפʵǽϡΥեե륻äƤ롢ȸȤǤޤ


ȤС

̿ưΥͥ륮λ (ATP)


̿ǽݤĤΥΥۥᥪǽ


˦٥ǤγԳʤɤʤɡ



եե륻ϡȤˡк˦䥷ʥץ¿¸ߤ[1]


륳ɡѥߥ󡢥Υ륢ɥʥȤäãʪФ䥷ʥã˴ͿƤޤ[2,3,4,5]



եե륻ΡƬǾؤͭˤĤơʳŪϼθ̤𤷤Ƥޤ


Ϥβ


ݸ


ȥ쥹


ĺ


ƬǾη򹯤ˤʤˤȤäơ

եե륻֥ץǤϤʤǤ礦



ˤʸϤǤ礦


ʿǯ20.4Фηͤоݤˤ祦եȥۥե륻ȤȤ߹碌ĴΤǤ


Ȥ߹碌Ϥ


1) 祦ե120 ñΤݼ褷硣


2) 祦ե120 ȥۥե륻 (PS) 360 Ʊݼ褷硣


3) 祦ե120 ȥۥե륳 (PC) 360 Ʊݼ褷硣


λѥǡָ


ϤΥԡɡ


Ϥ


ֵϤΥԡɡ


ֵ


󼡵


֥󥰥꡼ Ĵ٤Ƥޤ





) 祦եȥեե륻Ȥ߹碌

Ǥ̤ι⤤Ȥ߹碌Τ褦Ǥ


ϤΥԡɡ ˤƤ

˥祦եñ
˥祦եȥۥե륻
˥祦եȥեե륳󤬡2.5ָޤͭդ®ʤä


ˤΥ祦եȥեե륻Ʊݼϡ

ˡ6ָˤƤͭդ®



Ϥ Ǥ


˥祦եȥեե륻Ȥ߹碌ͭդʲߤ줿



ֵΥԡɡ Ǥ


˥祦եȥեե륳4ָ˵դ٤ʤä

˥祦եȥեե륻ϡ

ݼ裱֤飶ָΤ٤Ƥͭդ˲[6]



Υȥϡͤ˽񤭴٤⤷ޤ


Ǿη򹯤ˤϡեե륻ȥ祦եĤʻݤ٤Ǥ





ǤϤʤեե륻ϵϤΤǤ礦



Υᥫ˥ΤʲϤʤƤϤޤ󤬡

ˤʤΤǤϤʤǤ礦


륳ưʥץǽγ [7]


ʥãϤؤθ [8] [9]





ޤեե륻ϡݸѤͭƤޤ

ʥͥߤ˥եե륻 (200mg/kg,5) 򤢤餫ͿƤ顢ǾƣˡCA1ΰ (ξϵˤϽפΰǤ) οк˦ؤθ̤Ĵ٤


եե륻Ϳϡץ饻ܷ١к˦ؤΥ᡼ڸƤ[10]



ۤˤDz٤αɤ򵯤ǾȿФ (ȱֺ˦ȿ򹶷⤹륱) եե륻ϤαɤƯ򤷤Ƥޤ[13]





եե륻ϿĹҼοäޤ

Ĺ (Nerve growth factor: NGF) Ͽȯã򤦤ʤǽϤ餫륿ѥǤ[14]


ΤϤ餭ϡNGF ( ϤǾοк˦ɽ̤¸ߤ) NGF礹뤳ȤˤäƵޤ


NGFοϲȼ뤳ȤʬäƤޤ


åȤμ¸ˤƥեե륻ϡNGFοäƤޤ[15]


줬̣Τϡк˦ؤιϷѤǤ




ƱʸˤϡεҤ⸫ޤ

ˤäƿк˦μ͵Υѥ̩١˥塼ο礭ϸƤ椭ޤϷͥߤ˥եե륻 (50mg/kg,24) Ϳ̤ǤϡΤ褦ʸǧʤä[15]





եե륻ιȥ쥹Ѥ⸫ƨȤϤǤޤ

ȥ쥹ˤϡ뤬ޤ


ΤϡǾ (Ȥ˳) ʢ¿ȤΤƤޤ

ȥ쥹Ͽ徺׹ͤᤰ餻ʢˤϤäפȻä򤿤ᤳޤ롣

ͶƳ⡢ΰǤ


ʥϡк˦򳲤ޤ


Ϥοк˦μΤɷ㤷ֶʳ 򾷤Ǥ

ֶʳפȤϡ륷।󤬺˦˲ή뤳Ȥǡ

к˦ư򵯤˻ᥫ˥Ǥ



եե륻ϡβ껺ޤ

ȥȥ졼˥󥰤ǡСȥ졼˥󥰤ˤʤä˥եե륻 (800 /) ݼ褷Ȥȯᥫ˥Ǥ뾲--շϤѲ⤿餷뻺㲼[16,17,18]





եե륻ϡѤͭƤ褦Ǥ


԰¾㳲䤦ľɾβ[20]


ʡҸǽϤξ徺ǧ줿[16,19,20,21]






ȤǡǾͭפȤ륵ץȤФ뺬Ūʵϡ

ʪǾϤΤ

ä⡢ޤ

Ǿؤ̤BBB (Ǿ) ̤ȴ뤳ȤѺǤ


եե륻ϡиݼˤƤǾܹǧƤޤ[10]




ǤϺǸ

եե륻ϡɤΤ餤̤ݤɤΤǤ礦



ͤϡ100 ʾݼ褬ͭ[22]



ڷ

Ǿη򹯤ˤϡեե륻100 ݼ褹뤳ȡ



ȥ쥹¿ȿռԤƬǾϡˡ祦ե120 äݤɤǤ礦




SWITCH HYPER SWITCH ϡʬ̤¸Ƥޤ

ʬץˡ

祦ե120
եե륻100
ͥ줿ޡȥϡ֤Ǥ⤢ͻ200
Хѥ˥饨80

۹礵Ƥޤ



ǾΥѥեޥ󥹤ݤϡ
SWITCH ƤƤߤƤϤǤ礦

switch %282%29

hyper_switch %282%29

ޥŷǤǤޤ
Amazon
SWITCH
COOL SWITCH
HYPER SWITCH
ŷ
https://www.rakuten.co.jp/
iStock_000005716223XSmall


[1] Kidd PM. 1999. A review of nutrients and botanical in the integrative management of cognitive dysfunction. Altern Med Rev 4:38-43
[2] Bruni A,Toffano G.1982. Lysophophatidylserine, a short-lived intermediate with plasma membrane regulatory properties. Pharmaco Res Commun 14(6):469-484
[3] Yoshimura T, Sone S. 1990 Role of phosphatidylserine in membrane actions of tumor necrosis factor and interfoerons alpha and gamma. Biochem Int 20(4):697-705
[4] Cohen SA,Mueller WE.1992. Age related alterations in the mouse forebrain:partial restoration by chronic phosphatidylserine treatment. Brain Res 584: 174-180
[5] Moynagh PN, Williams DC.1992. Stabilization of the peripheral-type benzodiazepine acceptor by specific phospholipids. Biochem Pharmacol 43(9): 1939-1945
[6] D.O.Kennedy, C.F Haskell, P.L Mauri, A.B Scholey.2007. Acute cognitive effects of standardized Ginkgo biliba extract conplexed with phosphatidylserine. Hum.Psychopharmacol Clin Exp 2007 ;22:199-210
[7] Pedata F et.al. 1985. Phosphatidylserine increases acetylcholine release from cortical slices in aged rats. Neurobiol Aging 6(4): 337-339
[8] Benowitz LI et.al. 2000. GAP-43:an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 20(2):84-91
[9] Gianotti C et.al. 1993. B-50/GAP-43 phosphorylation in hippocampal slices from aged rats: effects of phosphatidylserine administration. Neurobiol Aging 14(5): 401-406
[10] , ƣ . 2010. Ʀۥե륻Ǿǽ Anti-aging Science 2(2): 57-61
[11] Calderon C, Huang ZH, Gage DA, et.al. 1994. Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidylserine. J Exp Med 180: 945-958
[12] Venema RC, Sayegh HS, Arnal JF, et.al. 1995. Role of enzyme calmodulin-binding domain in membrane association and phospholipid inhibition of endothelial nitric oxide synthase. J Bio Chem 270: 14705-14711
[13] Monastra G,Gross AH, Bruni A et.al. 1993. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelinaction. Neurology 43: 153-163
[14] Angelucci L, Ramacci MT, Taglialatela G, et.al. 1988. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neuroscience Res 20:491-496
[15] Nunzi MG, Milan F, Guidolin D, Toffano G. 1987. Dendritic spine loss in hippocampus of aged rats Effect of brain phosphatidylserine administration. Neurobiol Aging 8:501-510
[16] Cenacchi T, Bertoldin T, Farina C, et.al. 1993. Cognitive decline in the elderly: a double-blind,placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging(Milano) 5:123-133
[17] Monteleone P,Beinat L, Tanzillo C, et.al. 1990. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 52:243-248
[18] Monteleone P, Maj M, Beinat L, et.al. 1992. Blunting by chronic hosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol 42:385-388
[19] Maggioni M, Picotti GB, Bondiolotti GP,et.al. Effects of hosphatidylserine therapy in geriatric patients with depressive disdoers. Acta psychiatr Scand 81:265-270
[20] Crook T,Petrie W, Wells C, Massari DC. 1992. Effects of phosphatidylserine in Alzheimers disease. Psychopharmacol 42:385-388
[21] Amaducci L. 1988. Phosphatidylserine in the treatment of Alzheimers disease: results of a multicenter study. Psychopharmacol Bull 24:130-134
[22] Parris M. 1999. A review of nutrients and botanicals in the integratetive management of cognitive dysfunction. Alternative Medicine Review 4(3):144-161

ΥڡΥȥåץ